The Trump administration’s impact on gene therapy has been a topic of interest for researchers, advocates, and industry executives. Recently, the Food and Drug Administration (FDA) hosted a “Cell and Gene Therapy Roundtable” to address this issue.
The roundtable was described as an unusual event, with many panelists unsure of the agenda or purpose of the meeting. Despite this, guests from academia, advocacy, and industry were asked to share their insights on what the FDA should know about cell and gene therapy.
Following these statements, health secretary Robert F. Kennedy Jr., National Institutes of Health Director Jay Bhattacharya, and Centers for Medicare and Medicaid Services Administrator Mehmet Oz provided their perspectives. However, due to time constraints, there was limited opportunity for discussion or debate.
The Trump administration’s stance on gene therapy remains uncertain, with many questions still unanswered. It is crucial for stakeholders in the field to continue advocating for policies that support innovation and access to cutting-edge therapies.
As the landscape of gene therapy evolves, it is essential for the FDA and other regulatory bodies to stay informed and engaged with the latest advancements in the field. Collaboration between government agencies, researchers, and industry leaders will be key in ensuring that patients can benefit from the promise of gene therapy in the years to come.
